
The study demonstrated that tonabersat (TO), a blood–brain-barrier-penetrating drug, disrupts glioblastoma networks by inhibiting connexin 43 (Cx43)-based gap junctions (GJs). TO reduced intercellular cytosolic transfer, shortened tumor microtube length, and synergistically enhanced temozolomide-induced cell death. CRISPR/Cas9 Cx43-knockout confirmed that TO's effects depend on Cx43 GJ inhibition.
Like
Save
Share